共 133 条
[1]
Spreen W(2014)Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults J Acquir Immune Defic Syndr. 67 487-492
[2]
Williams P(2000)Factors affecting adherence to antiretroviral therapy Clin Infect Dis. 30 S171-S176
[3]
Margolis D(2013)Long-acting injectable antiretrovirals for HIV treatment and prevention Curr Opin HIV AIDS. 8 565-571
[4]
Chesney MA(2009)Pediatric adherence to HIV antiretroviral therapy Curr HIV/AIDS Rep. 6 194-200
[5]
Spreen WR(2016)Efficacy of long-acting injectable antipsychotics in adolescents J Child Adolesc Psychopharmacol. 26 391-394
[6]
Margolis DA(2015)Two cases of long-acting paliperidone in adolescence Ther Adv Psychopharmacol. 5 304-306
[7]
Pottage JCJ(2010)Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation Antimicrob Agents Chemother. 54 2042-2050
[8]
Haberer J(2015)Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial Lancet Infect Dis. 15 1145-1155
[9]
Mellins C(2012)Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials Clin Pharmacol Ther. 91 926-931
[10]
Pope S(2005)Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs Br J Clin Pharmacol. 59 691-704